Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:52:50.555Z.
Calculation as of: 2026-10-06T16:52:50.555Z.
Quote observation: 2026-10-06T16:48:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$11.46M
EV/FCF Ratio
N/A
TTM Avg
5.23x
3Y Avg
5.23x
5Y Avg
5.23x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pluri Inc. (PLUR) | $11.33M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.61M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.46M | N/A | 5.23x | 5.23x | 5.23x |
| BioVie Inc. (BIVI)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.47M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.90M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 7.58x | 7.58x | 7.58x |
| Caring Brands, Inc. (CABR)vs › | $10.73M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
